Compare EBC & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EBC | ADPT |
|---|---|---|
| Founded | 1818 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.1B |
| IPO Year | 2020 | 2019 |
| Metric | EBC | ADPT |
|---|---|---|
| Price | $22.36 | $26.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $22.70 | $17.78 |
| AVG Volume (30 Days) | ★ 2.5M | 2.4M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.02% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 0.77 | N/A |
| Revenue | $134,091,000.00 | ★ $276,976,000.00 |
| Revenue This Year | $80.92 | $3.98 |
| Revenue Next Year | $4.44 | $22.72 |
| P/E Ratio | $29.40 | ★ N/A |
| Revenue Growth | 19.07 | ★ 54.77 |
| 52 Week Low | $16.62 | $12.00 |
| 52 Week High | $23.78 | $26.16 |
| Indicator | EBC | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 44.19 | 61.22 |
| Support Level | $22.04 | $23.92 |
| Resistance Level | $22.73 | $26.16 |
| Average True Range (ATR) | 0.41 | 1.03 |
| MACD | -0.14 | -0.07 |
| Stochastic Oscillator | 31.70 | 75.64 |
Eastern Bankshares Inc is a commercial bank that caters its products and services to retail, commercial, and small business customers. Its diversified products and services include lending, deposit, wealth management, and insurance products. The company has one operating segment: Banking business, which offers a range of banking, lending, savings, and small business offerings, and its wealth management and trust operations.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.